RXRX - RECURSION PHARMACEUTICALS, INC.
IEX Last Trade
7.28
-0.070 -0.962%
Share volume: 180,387
Last Updated: Fri 27 Dec 2024 05:30:34 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$7.35
-0.07
-0.95%
Fundamental analysis
8%
Profitability
0%
Dept financing
8%
Liquidity
71%
Performance
1%
Performance
5 Days
3.58%
1 Month
22.92%
3 Months
0.98%
6 Months
-17.35%
1 Year
-32.90%
2 Year
1.12%
Key data
Stock price
$7.28
DAY RANGE
$7.05 - $7.72
52 WEEK RANGE
$5.99 - $15.74
52 WEEK CHANGE
-$31.76
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Chistopher C. Gibson
Region: US
Website: recursion.com
Employees: 400
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: recursion.com
Employees: 400
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Recursion Pharmaceuticals, Inc. engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation. REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer.
Recent news